Rhabdomyosarcoma of Parameningeal Sites

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Neuro-oncology

Background:

• Skull base rhabdomyosarcoma is a rare pediatric cancer with unique invasive potential.
• Parameningeal sites (nasopharynx, middle ear, sinuses, infratemporal fossa) account for a significant proportion of head and neck rhabdomyosarcoma.
• This tumor can extend intracranially, leading to neoplastic meningitis.

Purpose of the Study:

• To review the natural history, treatment evolution, and outcomes of skull base rhabdomyosarcoma.
• To evaluate the impact of refined radiation therapy protocols on patient survival and late effects.
• To identify risk factors influencing treatment timing and central nervous system relapse.

Main Methods:

• Analysis of data from Intergroup Rhabdomyosarcoma Study (IRS) protocols over 20 years.
• Review of radiation treatment parameters, including dosage, margins, and timing relative to chemotherapy.
• Assessment of risk factors (skull base erosion, cranial nerve palsy, intracranial extension) for predicting subarachnoid space involvement.

Main Results:

• Improved outcomes with refined IRS protocols, including reduced whole cranial radiotherapy.
• 5-year failure-free survival for Group III parameningeal rhabdomyosarcoma was 71% on IRS-III.
• In the absence of specific risk factors, 5-year survival reached 97%, with a 15% local failure rate.
• Central nervous system failure occurred in 5% of patients with complete or partial response.

Conclusions:

• Current IRS guidelines optimize radiation therapy for skull base rhabdomyosarcoma, balancing efficacy and toxicity.
• Risk factor assessment is crucial for tailoring treatment timing and minimizing central nervous system relapse.
• Ongoing treatment refinements hold promise for further improving the therapeutic ratio and reducing late effects in young patients.